Compare TRUP & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRUP | AUPH |
|---|---|---|
| Founded | 2000 | 1993 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2014 | 2014 |
| Metric | TRUP | AUPH |
|---|---|---|
| Price | $28.90 | $14.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $45.50 | $17.25 |
| AVG Volume (30 Days) | 530.0K | ★ 715.2K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 295.65 | N/A |
| EPS | 0.45 | ★ 0.55 |
| Revenue | ★ $1,439,305,000.00 | $235,133,000.00 |
| Revenue This Year | $12.42 | $21.76 |
| Revenue Next Year | $9.39 | $16.45 |
| P/E Ratio | $64.22 | ★ $25.97 |
| Revenue Growth | ★ 11.95 | N/A |
| 52 Week Low | $27.30 | $6.83 |
| 52 Week High | $57.35 | $16.54 |
| Indicator | TRUP | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 33.08 | 43.06 |
| Support Level | $27.30 | $14.18 |
| Resistance Level | $34.42 | $14.66 |
| Average True Range (ATR) | 1.57 | 0.43 |
| MACD | -0.25 | 0.00 |
| Stochastic Oscillator | 24.44 | 20.74 |
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.